MedTrace Logo

Benign Migratory Glossitis Associated With Antiangiogenic Drugs

NCT06988865 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2025-05-25

No results posted yet for this study

Summary

Oral clinical descriptions related to adverse events in patients treated with those elective multi-targeted receptor tyrosine kinase inhibitors and a recombinant humanised monoclonal antibody

Conditions

Interventions

OTHER

Clinical evaluation

treatment methods, associated symptoms, evolution and clinical presentation

Sponsors & Collaborators

  • Instituto do Cancer do Estado de São Paulo

    lead OTHER

Principal Investigators

  • Mauricio Neves Gomes, PhD · Instituto do Cancer do Estado de São Paulo

  • Wagner Gomes da Silva, PhD · Instituto do Cancer do Estado de São Paulo

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-16
Primary Completion
2020-01-10
Completion
2024-02-01

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06988865 on ClinicalTrials.gov